The latest price target for Summit Therapeutics (NASDAQ:SMMT) was reported by Goldman Sachs on February 28, 2025. The analyst firm set a price target for $42.00 expecting SMMT to rise to within 12 months (a possible 133.33% upside). 27 analyst firms have reported ratings in the last year.

The latest analyst rating for Summit Therapeutics (NASDAQ:SMMT) was provided by Goldman Sachs, and Summit Therapeutics initiated their buy rating.

There is no last upgrade for Summit Therapeutics

The last downgrade for Summit Therapeutics Inc happened on September 27, 2024 when Citigroup changed their price target from $19 to $23 for Summit Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Summit Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Summit Therapeutics was filed on February 28, 2025 so you should expect the next rating to be made available sometime around February 28, 2026.

While ratings are subjective and will change, the latest Summit Therapeutics (SMMT) rating was a initiated with a price target of $0.00 to $42.00. The current price Summit Therapeutics (SMMT) is trading at is $18.00, which is within the analyst’s predicted range.